A new cost analysis finds that matching relapsed lymphoma treatment to a personalized drug-response test was associated with longer disease control and a lower estimated daily treatment cost in dogs.
|Articles|March 7, 2011
Today's Daily Dose: Hemangiosarcoma
What you need to know about these indolent tumors.
Advertisement
Untitled Document
“Hemangiosarcoma is extremely indolent, so clinical signs are usually not evident until the advanced stage when metastasis has occurred. The tumors at this stage are largely resistant to chemotherapy, and standard-of-care (surgery and intensive chemotherapy) provides a median survival of little more than six months. Morbidity and mortality are usually due to acute internal hemorrhage secondary to tumor rupture.”
Advertisement
Advertisement
Related to this article
Verdinexor tablets are now available for dogs with lymphoma after receiving full FDA approval earlier this year, offering an at-home treatment option given twice weekly and showing a longer time to disease progression than the control in a field study.
Preclinical testing at The Ohio State University found Telomir-Zn inhibited the growth of canine and human osteosarcoma cell lines, prompting the company to explore a possible in vivo study in dogs with naturally occurring tumors.
Caroline Cox, LSW, MSW, and Erika Krick, VMD, DACVIM (Oncology), discuss the role of veterinary social workers in supporting clients, communicating with veterinary teams, and helping practices address the human side of veterinary care in this Q&A from an interview at the 2026 Fetch National Harbor Veterinary Conference.
Advertisement
Advertisement
Trending on dvm360
1
Pets may help older adults who live alone stay active and connected, survey finds
2
How a structured, multisensory approach can improve the preventive care experience for pets and clients
3
Outpatient surgery for animals with pyometra provides good outcome for dogs and cats
4
Q&A Stuck in the red zone? How veterinary teams can reset after conflict
5